MANKINDPharmaceuticals
Mankind Pharma Ltd — PE Ratio & Valuation Analysis
₹2005.80
+0.73%
Current P/E52.62xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E55.7x5.5% below avg
⚠️
65.6% Premium to Industry
MANKIND P/E 52.62x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹49.20 | ₹2197 | 44.6x |
| 2024 | ₹47.68 | ₹2880 | 60.4x |
| 2023 | ₹32.00 | ₹1983 | 62x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Mankind Pharma Ltd Valuation
Mankind Pharma Ltd (MANKIND) currently trades at 52.62x earnings. The Pharmaceuticals sector average PE is 31.77x. MANKIND commands a premium, reflecting high growth expectations. Historically, MANKIND has traded at an average PE of 55.7x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
14.68%
Dividend Yield
0.04%
More on Mankind Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.